cnv

CNV Dopamine is a carboxynitroveratryl (CNV)-caged dopamine; releases dopamine upon ultraviolet light stimulation (365 nm). Induces dopaminergic currents upon photolysis in brain slices expressing wild-type or GFP-labeled D2receptors. Displays no decrease in current (rundown) with UV light flash duration of up to 100 ms. Pharmacologically inactive prior to photolysis.

CNV-2197944 is a novel, small molecule, state-dependent calcium channel blocker, designed to selectively inhibit highly active Cav2.2 channels.

Raxatrigine (CNV 1014802) has been investigated for the treatment of Bipolar Disorder and Bipolar Depression.

ω-Conotoxin CnVIIA, a 27-amino-acid neuropeptide toxin, serves as an N-type calcium current blocker [1].

Bevasiranib, a siRNA, is specifically engineered to suppress the expression of genes responsible for the production of vascular endothelial growth factor (VEGF), a critical factor in the development of choroidal neo-vascularization (CNV), which precedes wet age-related macular degeneration (wet AMD).

SC 46944 is a highly potent human renin inhibitor.

Bevasiranib sodium, an siRNA compound, targets and silences the genes responsible for producing vascular endothelial growth factor (VEGF). The suppression of VEGF, a critical factor in the development of choroidal neo-vascularization (CNV), aims to thwart the progression to wet age-related macular degeneration (wet AMD).

SH-11037 is a novel potent seh inhibitor, effectively blocking key angiogenic properties of human retinal endothelial cells (hrecs), inhibiting choroidal sprouting and significantly suppressing cnv lesion volume

Mecamylamine hydrochloride (Mevasin) is a nicotinic antagonist, used as a ganglionic blocker in hypertension.

Raxatrigine hydrochloride is a state-dependent sodium channel blocker and a Nav1.7 sodium channel inhibitor.

IMS2186 is a reagent with activity of antichoroidal neovascularization (CNV). IMS2186 could arrest cancer cell cycle in G2 M phase, result in exerting anti-proliferation and anti-angiogenesis effects. IMS2186 reduces the amount of eye leakage and diseased cells with no intraocular toxicity.